| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.12 | 6e-05 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |